Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "AIM-HN Study Evaluating Tipifarnib in mHRAS, Recurrent/Metastatic HNSCC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alan Ho
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alan Ho
Login to view comments.
Click here to Login
Head and Neck